Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Helicidine→

Helicidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
215369-37-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Non-opioid antitussivesnail-derived glycoprotein cough suppressant
Mechanism of action
A glycoprotein extract from Helix pomatia mucus with proposed peripheral effects on airway sensory receptors and cough-reflex pathways. The precise mechanism is not established, and published clinical evidence supporting efficacy in acute cough is lacking.
Indications / reported uses
  • Historically marketed in some countries for symptomatic relief of cough. Published evidence is insufficient to establish clinical efficacy for acute cough or acute bronchitis; this entry is historical/regional rather than a confirmed standard treatment.

Sources: https://bmjopenrespres.bmj.com/content/3/1/e000137 · https://www.ncbi.nlm.nih.gov/mesh/?term=helicidine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Helicidine Environmental Risk Assessment (ERA) (the Helicidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.